Exploring biological mechanisms and identifying biomarkers that predict the risk of lymphoma will further enhance current understandings of the lymphoma risk in RA patients treated with anti-TNF-α agents and inform personalized treatment approaches for patients with RA. This evidence concerns the gene TNF and rheumatoid arthritis.